The tumor microenvironment: Characterization, redox considerations, and novel approaches for reactive oxygen species-targeted gene therapy

Antioxidants and Redox Signaling

Volumn 19, Issue 8, 2013, Pages 854-895

  Policastro, Lucia Laura ^a,b   Ibañez, Irene Laura ^b   Notcovich, Cintia ^a   Duran, Hebe Alicia ^a,b,c   Podhajcer, Osvaldo Luis ^b,d  

^a DEPARTAMENTO DE FÍSICA   (Argentina)

^b Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^c UNIVERSIDAD NACIONAL DE SAN MARTÍN   (Argentina)

^d FUNDACIÓN INSTITUTO LELOIR   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTATHIONE PEROXIDASE; PEROXIREDOXIN; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE;

ANGIOGENESIS; CANCER CELL; CANCER GENE THERAPY; CANCER INHIBITION; CELL METABOLISM; DEATH; EXTRACELLULAR MATRIX; FIBROBLAST; GENE OVEREXPRESSION; HOMEOSTASIS; HUMAN; HYPOXIA; INFLAMMATORY CELL; PRIORITY JOURNAL; REVIEW; STROMA CELL; SURVIVAL; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION;

ANIMALS; ANTIOXIDANTS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC THERAPY; HUMANS; NEOPLASMS; OXIDATION-REDUCTION; OXIDATIVE STRESS; OXIDOREDUCTASES; REACTIVE OXYGEN SPECIES; TUMOR MICROENVIRONMENT;

EID: 84882684320     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2011.4367     Document Type: Review

References (354)

1. Acharya A, Das I, Chandhok D, and Saha T. Redox regulation in cancer: a double-edged sword with therapeutic potential. Oxid Med Cell Longev 3: 23-34, 2010.
2. Achuthan S, Santhoshkumar TR, Prabhakar J, Nair SA, and Pillai MR. Drug-induced senescence generates chemoresistant stemlike cells with low reactive oxygen species. J Biol Chem 286: 37813-37829, 2011.
3. Adlakha YK and Saini N. MicroRNA-128 downregulates Bax and induces apoptosis in human embryonic kidney cells. Cell Mol Life Sci 68: 1415-1428, 2011.
4. Ahmad IM, Aykin-Burns N, Sim JE, Walsh SA, Higashikubo R, Buettner GR, Venkataraman S, Mackey MA, Flanagan SW, Oberley LW, and Spitz DR. Mitochondrial O2*-and H2O2 mediate glucose deprivation-induced stress in human cancer cells. J Biol Chem 280: 4254-4263, 2005.
5. Ahmed Z and Bicknell R. Angiogenic signalling pathways. Methods Mol Biol 467: 3-24, 2009.
6. Albertson DG, Collins C, McCormick F and Gray JW. Chromosome aberrations in solid tumors. Nat Genet 34: 369-376, 2003.
7. Albertsson PA, Basse PH, Hokland M, Goldfarb RH, Nagelkerke JF, Nannmark U, and Kuppen PJ. NK cells and the tumour microenvironment: implications for NK-cell function and anti-tumour activity. Trends Immunol 24: 603-609, 2003.
8. Allavena P, Sica A, Solinas G, Porta C, and Mantovani A. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol Hematol 66: 1-9, 2008.
9. Alvarez MJ, Prada F, Salvatierra E, Bravo AI, Lutzky VP, Carbone C, Pitossi FJ, Chuluyan HE, and Podhajcer OL. Secreted protein acidic and rich in cysteine produced by human melanoma cells modulates polymorphonuclear leukocyte recruitment and antitumor cytotoxic capacity. Cancer Res 65: 5123-5132, 2005.
10. Antico Arciuch VG, Elguero ME, Poderoso JJ, and Carreras MC. Mitochondrial regulation of cell cycle and proliferation. Antioxid Redox Signal 16: 1150-1180, 2012.
11. Antico Arciuch VG, Galli S, Franco MC, Lam PY, Cadenas E, Carreras MC, and Poderoso JJ. Akt1 intramitochondrial cycling is a crucial step in the redox modulation of cell cycle progression. PLoS One 4: e7523, 2009.
12. Arbiser JL, Petros J, Klafter R, Govindajaran B, McLaughlin ER, Brown LF, Cohen C, Moses M, Kilroy S, Arnold RS, and Lambeth JD. Reactive oxygen generated by Nox1 triggers the angiogenic switch. Proc Natl Acad Sci U S A 99: 715-720, 2002.
13. Arner ES. Focus on mammalian thioredoxin reductases-important selenoproteins with versatile functions. Biochim Biophys Acta 1790: 495-526, 2009.
14. Arner ES and Holmgren A. The thioredoxin system in cancer. Semin Cancer Biol 16: 420-426, 2006.
15. Arnold SA, Rivera LB, Miller AF, Carbon JG, Dineen SP, Xie Y, Castrillon DH, Sage EH, Puolakkainen P, Bradshaw AD, and Brekken RA. Lack of host SPARC enhances vascular function and tumor spread in an orthotopic murine model of pancreatic carcinoma. Dis Model Mech 3: 57-72, 2010.
16. Azad MB, Chen Y, and Gibson SB. Regulation of autophagy by reactive oxygen species (ROS): implications for cancer progression and treatment. Antioxid Redox Signal 11: 777-790, 2009.
17. Backman E, Bergh AC, Lagerdahl I, Rydberg B, Sundstrom C, Tobin G, Rosenquist R, Linderholm M, and Rosen A. Thioredoxin, produced by stromal cells retrieved from the lymph node microenvironment, rescues chronic lymphocytic leukemia cells from apoptosis in vitro. Haematologica 92: 1495-1504, 2007.
18. Baggetto LG. Deviant energetic metabolism of glycolytic cancer cells. Biochimie 74: 959-974, 1992.
19. Bahar G, Feinmesser R, Shpitzer T, Popovtzer A, and Nagler RM. Salivary analysis in oral cancer patients: DNA and protein oxidation, reactive nitrogen species, and antioxidant profile. Cancer 109: 54-59, 2007.
20. Baj-Krzyworzeka M, Baran J, Weglarczyk K, Szatanek R, Szaflarska A, Siedlar M, and Zembala M. Tumour-derived microvesicles (TMV) mimic the effect of tumour cells on monocyte subpopulations. Anticancer Res 30: 3515-3519, 2010.
21. Balkwill F and Mantovani A. Inflammation and cancer: back to Virchow? Lancet 357: 539-545, 2001.
22. Banjac A, Perisic T, Sato H, Seiler A, Bannai S, Weiss N, Kolle P, Tschoep K, Issels RD, Daniel PT, Conrad M, and Bornkamm GW. The cystine/cysteine cycle: a redox cycle regulating susceptibility versus resistance to cell death. Oncogene 27: 1618-1628, 2008.
23. Banning A, Kipp A, Schmitmeier S, Lowinger M, Florian S, Krehl S, Thalmann S, Thierbach R, Steinberg P, and Brigelius-Flohe R. Glutathione peroxidase 2 inhibits cyclooxygenase-2-mediated migration and invasion of HT-29 adenocarcinoma cells but supports their growth as tumors in nude mice. Cancer Res 68: 9746-9753, 2008.
24. Bedard K and Krause KH. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 87: 245-313, 2007.
25. Bergers G and Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3: 401-410, 2003.
26. Bertout JA, Patel SA, and Simon MC. The impact of O2 availability on human cancer. Nat Rev Cancer 8: 967-975, 2008.
27. Bissell MJ and Radisky D. Putting tumours in context. Nat Rev Cancer 1: 46-54, 2001.
28. Bornstein P. Matricellular proteins: an overview. J Cell Commun Signal 3: 163-165, 2009.
29. Borrelli A, Schiattarella A,Mancini R, Morrica B, Cerciello V, Mormile M, d'Alesio V, Bottalico L, Morelli F, D'Armiento M, D'Armiento FP, and Mancini A. A recombinant MnSOD is radioprotective for normal cells and radiosensitizing for tumor cells. Free Radic Biol Med 46: 110-116, 2009.
30. Brahimi-Horn MC, Bellot G, and Pouyssegur J. Hypoxia and energetic tumour metabolism. Curr Opin Genet Dev 21: 67-72, 2011.
31. Brahimi-Horn MC, Chiche J, and Pouyssegur J. Hypoxia signalling controls metabolic demand. Curr Opin Cell Biol 19: 223-229, 2007.
32. Brand MD. The sites and topology of mitochondrial superoxide production. Exp Gerontol 45: 466-472, 2010.
33. Bristow RG and Hill RP. Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer 8: 180-192, 2008.
34. Brown JM and Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 4: 437-447, 2004.
35. Bussolati B, Deregibus MC, and Camussi G. Characterization of molecular and functional alterations of tumor endothelial cells to design anti-angiogenic strategies. Curr Vasc Pharmacol 8: 220-232, 2010.
36. Bussolati B, Grange C, and Camussi G. Tumor exploits alternative strategies to achieve vascularization. FASEB J 25, 2874-2882, 2011.
37. Cabarcas SM, Mathews LA, and Farrar WL. The cancer stem cell niche-there goes the neighborhood? Int J Cancer 129: 2315-2327, 2011.
38. Cadenas E, Boveris A, Ragan CI, and Stoppani AO. Production of superoxide radicals and hydrogen peroxide by NADH-ubiquinone reductase and ubiquinol-cytochrome c reductase from beef-heart mitochondria. Arch Biochem Biophys 180: 248-257, 1977.
39. Cairns RA, Harris IS, and Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer 11: 85-95, 2011.
40. Cao Y, Cao R, and Hedlund EM. R Regulation of tumor angiogenesis and metastasis by FGF and PDGF signaling pathways. J Mol Med (Berl) 86: 785-789, 2008.
41. Carmeliet P and Jain RK. Angiogenesis in cancer and other diseases. Nature 407: 249-257, 2000.
42. Carr A and Frei B. Does vitamin C act as a pro-oxidant under physiological conditions? FASEB J 13: 1007-1024, 1999.
43. Carreras MC and Poderoso JJ. Mitochondrial nitric oxide in the signaling of cell integrated responses. Am J Physiol Cell Physiol 292: C1569-C1580, 2007.
44. Ceccarelli J, Delfino L, Zappia E, Castellani P, Borghi M, Ferrini S, Tosetti F, and Rubartelli A. The redox state of the lung cancer microenvironment depends on the levels of thioredoxin expressed by tumor cells and affects tumor progression and response to prooxidants. Int J Cancer 123: 1770-1778, 2008.
45. Chandel NS, McClintock DS, Feliciano CE, Wood TM, Melendez JA, Rodriguez AM, and Schumacker PT. Reactive oxygen species generated at mitochondrial complex III stabilize hypoxia-inducible factor-1alpha during hypoxia: a mechanism of O2 sensing. J Biol Chem 275: 25130-25138, 2000.
46. Chandramathi S, Suresh K, Anita ZB, and Kuppusamy UR. Comparative assessment of urinary oxidative indices in breast and colorectal cancer patients. J Cancer Res Clin Oncol 135: 319-323, 2009.
47. Chang D, Wang F, Zhao YS, and Pan HZ. Evaluation of oxidative stress in colorectal cancer patients. Biomed Environ Sci 21: 286-289, 2008.
48. Chang Q, Pan J, Wang X, Zhang Z, Chen F, and Shi X. Reduced reactive oxygen species-generating capacity contributes to the enhanced cell growth of arsenic-transformed epithelial cells. Cancer Res 70: 5127-5135, 2010.
49. Che ZM, Jung TH, Choi JH, Yoon do J, Jeong HJ, Lee EJ, and Kim J. Collagen-based co-culture for invasive study on cancer cells-fibroblasts interaction. Biochem Biophys Res Commun 346: 268-275, 2006.
50. Chen K and Chen X. Positron emission tomography imaging of cancer biology: current status and future prospects. Semin Oncol 38: 70-86, 2011.
51. Chen MF, Keng PC, Shau H, Wu CT, Hu YC, Liao SK, and Chen WC. Inhibition of lung tumor growth and augmentation of radiosensitivity by decreasing peroxiredoxin I expression. Int J Radiat Oncol Biol Phys 64: 581-591, 2006.
52. Chen MF, Lee KD, Yeh CH, Chen WC, Huang WS, Chin CC, Lin PY, and Wang JY. Role of peroxiredoxin I in rectal cancer and related to p53 status. Int J Radiat Oncol Biol Phys 78: 868-878, 2010.
53. Chen RS, Song YM, Zhou ZY, Tong T, Li Y, Fu M, Guo XL, Dong LJ, He X, Qiao HX, Zhan QM, and Li W. Disruption of xCT inhibits cancer cell metastasis via the caveolin-1/ beta-catenin pathway. Oncogene 28: 599-609, 2009.
54. Cheng MY, Lee IP, Jin M, Sun G, Zhao H, Steinberg GK, and Sapolsky RM. An insult-inducible vector system activated by hypoxia and oxidative stress for neuronal gene therapy. Transl Stroke Res 2: 92-100, 2011.
55. Chiche J, Brahimi-Horn MC, and Pouyssegur J. Tumour hypoxia induces a metabolic shift causing acidosis: a common feature in cancer. J Cell Mol Med 14: 771-794, 2010.
56. Chiche J, Ilc K, Laferriere J, Trottier E, Dayan F, Mazure NM, Brahimi-Horn MC, and Pouyssegur J. Hypoxiainducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH. Cancer Res 69: 358-368, 2009.
57. Christofk HR, Vander Heiden MG, Wu N, Asara JM, and Cantley LC. Pyruvate kinase M2 is a phosphotyrosinebinding protein. Nature 452: 181-186, 2008.
58. Chua PJ, Lee EH, Yu Y, Yip GW, Tan PH, and Bay BH. Silencing the peroxiredoxin III gene inhibits cell proliferation in breast cancer. Int J Oncol 36: 359-364, 2010.
59. Church SL, Grant JW, Ridnour LA, Oberley LW, Swanson PE, Meltzer PS, and Trent JM. Increased manganese superoxide dismutase expression suppresses the malignant phenotype of human melanoma cells. Proc Natl Acad Sci U S A 90: 3113-3117, 1993.
60. Circu ML and Aw TY. Reactive oxygen species, cellular redox systems, and apoptosis. Free Radic Biol Med 48: 749-762, 2010.
61. Citrin D, Camphausen K, Wood BJ, Quezado M, Denobile J, Pingpank JF, Royal RE, Alexander HR, Seidel G, Steinberg SM, Shuttack Y, and Libutti SK. A pilot feasibility study of TNFerade biologic with capecitabine and radiation therapy followed by surgical resection for the treatment of rectal cancer. Oncology 79: 382-388, 2010.
62. Clevers H. The cancer stem cell: premises, promises and challenges. Nat Med 17: 313-319, 2011.
63. Corzo CA, Condamine T, Lu L, Cotter MJ, Youn JI, Cheng P, Cho HI, Celis E, Quiceno DG, Padhya T, McCaffrey TV, McCaffrey JC, and Gabrilovich DI. HIF-1alpha regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med 207: 2439-2453, 2010.
64. Corzo CA, Cotter MJ, Cheng P, Cheng F, Kusmartsev S, Sotomayor E, Padhya T, McCaffrey TV, McCaffrey JC, and Gabrilovich DI. Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. J Immunol 182: 5693-5701, 2009.
65. Coulter JA, McCarthy HO,Worthington J, Robson T, Scott S, and Hirst DG. The radiation-inducible pE9 promoter driving inducible nitric oxide synthase radiosensitizes hypoxic tumour cells to radiation. Gene Ther 15: 495-503, 2008.
66. Coussens LM and Werb Z. Inflammation and cancer. Nature 420: 860-867, 2002.
67. Cox TR and Erler JT. Remodeling and homeostasis of the extracellular matrix: implications for fibrotic diseases and cancer. Dis Model Mech 4: 165-178, 2011.
68. Cutler RG, Plummer J, Chowdhury K, and Heward C. Oxidative stress profiling: part II. Theory, technology, and practice. Ann N Y Acad Sci 1055: 136-158, 2005.
69. Datta R, Taneja N, Sukhatme VP, Qureshi SA, Weichselbaum R, and Kufe DW. Reactive oxygen intermediates target CC(A/T)6GG sequences to mediate activation of the early growth response 1 transcription factor gene by ionizing radiation. Proc Natl Acad Sci U S A 90: 2419-2422, 1993.
70. De Simoni S, Goemaere J, and Knoops B. Silencing of peroxiredoxin 3 and peroxiredoxin 5 reveals the role of mitochondrial peroxiredoxins in the protection of human neuroblastoma SH-SY5Y cells toward MPP+ . Neurosci Lett 433: 219-224, 2008.
71. de Visser KE, Eichten A, and Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 6: 24-37, 2006.
72. Dearling JL, Flynn AA, Sutcliffe-Goulden J, Petrie IA, Boden R, Green AJ, Boxer GM, Begent RH, and Pedley RB. Analysis of the regional uptake of radiolabeled deoxyglucose analogs in human tumor xenografts. J Nucl Med 45: 101-107, 2004.
73. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, and Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 7: 11-20, 2008.
74. Demizu Y, Sasaki R, Trachootham D, Pelicano H, Colacino JA, Liu J, and Huang P. Alterations of cellular redox state during NNK-induced malignant transformation and resistance to radiation. Antioxid Redox Signal 10: 951-961, 2008.
75. DeNardo DG, Andreu P, and Coussens LM. Interactions between lymphocytes and myeloid cells regulate pro-versus anti-tumor immunity. Cancer Metastasis Rev 29: 309-316, 2010.
76. DeNicola GM, Karreth FA, Humpton TJ, Gopinathan A, Wei C, Frese K, Mangal D, Yu KH, Yeo CJ, Calhoun ES, Scrimieri F, Winter JM, Hruban RH, Iacobuzio-Donahue C, Kern SE, Blair IA, and Tuveson DA. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 475: 106-109, 2011.
77. Denko NC. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer 8: 705-713, 2008.
78. Dewhirst MW. Relationships between cycling hypoxia, HIF-1, angiogenesis and oxidative stress. Radiat Res 172: 653-665, 2009.
79. Dewhirst MW, Cao Y, and Moeller B. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer 8: 425-437, 2008.
80. Diaz B, Shani G, Pass I, Anderson D, Quintavalle M, and Courtneidge SA. Tks5-dependent, nox-mediated generation of reactive oxygen species is necessary for invadopodia formation. Sci Signal 2: ra53, 2009.
81. Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN, Qian D, Lam JS, Ailles LE, Wong M, Joshua B, Kaplan MJ, Wapnir I, Dirbas FM, Somlo G, Garberoglio C, Paz B, Shen J, Lau SK, Quake SR, Brown JM, Weissman IL, and Clarke MF. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 458: 780-783, 2009.
82. Ding WQ and Lind SE. Phospholipid hydroperoxide glutathione peroxidase plays a role in protecting cancer cells from docosahexaenoic acid-induced cytotoxicity. Mol Cancer Ther 6: 1467-1474, 2007.
83. Dixit D, Sharma V, Ghosh S, Koul N, Mishra PK, and Sen E. Manumycin inhibits STAT3, telomerase activity, and growth of glioma cells by elevating intracellular reactive oxygen species generation. Free Radic Biol Med 47: 364-374, 2009.
84. Dlaskova A, Hlavata L, and Jezek P. Oxidative stress caused by blocking of mitochondrial complex I H( + ) pumping as a link in aging/disease vicious cycle. Int J Biochem Cell Biol 40: 1792-1805, 2008.
85. Dome B, Hendrix MJ, Paku S, Tovari J, and Timar J. Alternative vascularization mechanisms in cancer: pathology and therapeutic implications. Am J Pathol 170: 1-15, 2007.
86. Droge W. Free radicals in the physiological control of cell function. Physiol Rev 82: 47-95, 2002.
87. Du J, Liu J, Smith BJ, Tsao MS, and Cullen JJ. Role of Rac1-dependent NADPH oxidase in the growth of pancreatic cancer. Cancer Gene Ther 18: 135-143, 2011.
88. Dunn LL, Buckle AM, Cooke JP, and Ng MK. The emerging role of the thioredoxin system in angiogenesis. Arterioscler Thromb Vasc Biol 30: 2089-2098, 2010.
89. Elsabahy M, Nazarali A, and Foldvari M. Non-viral nucleic acid delivery: key challenges and future directions. Curr Drug Deliv 8: 235-244, 2011.
90. Epperly MW, Melendez JA, Zhang X, Nie S, Pearce L, Peterson J, Franicola D, Dixon T, Greenberger BA, Komanduri P, Wang H, and Greenberger JS. Mitochondrial targeting of a catalase transgene product by plasmid liposomes increases radioresistance in vitro and in vivo. Radiat Res 171: 588-595, 2009.
91. Epperly MW, Wegner R, Kanai AJ, Kagan V, Greenberger EE, Nie S, and Greenberger JS. Effects of MnSOD-plasmid liposome gene therapy on antioxidant levels in irradiated murine oral cavity orthotopic tumors. Radiat Res 167: 289-297, 2007.
92. Eriksson SE, Prast-Nielsen S, Flaberg E, Szekely L, and Arner ES. High levels of thioredoxin reductase 1 modulate drug-specific cytotoxic efficacy. Free Radic Biol Med 47: 1661-1671, 2009.
93. Evans MD, Dizdaroglu M, and Cooke MS. Oxidative DNA damage and disease: induction, repair and significance. Mutat Res 567: 1-61, 2004.
94. Fang J, Seki T, and Maeda H. Therapeutic strategies by modulating oxygen stress in cancer and inflammation. Adv Drug Deliv Rev 61: 290-302, 2009.
95. Federico A, Morgillo F, Tuccillo C, Ciardiello F, and Loguercio C. Chronic inflammation and oxidative stress in human carcinogenesis. Int J Cancer 121: 2381-2386, 2007.
96. Ferbeyre G and Moriggl R. The role of Stat5 transcription factors as tumor suppressors or oncogenes. Biochim Biophys Acta 1815: 104-114, 2011.
97. Fischer K, Hoffmann P, Voelkl S, Meidenbauer N, Ammer J, Edinger M, Gottfried E, Schwarz S, Rothe G, Hoves S, Renner K, Timischl B, Mackensen A, Kunz-Schughart L, Andreesen R, Krause SW, and Kreutz M. Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood 109: 3812-3819, 2007.
98. Folberg R, Hendrix MJ, and Maniotis AJ. Vasculogenic mimicry and tumor angiogenesis. Am J Pathol 156: 361-381, 2000.
99. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182-1186, 1971.
100. Frey RS, Ushio-Fukai M, and Malik AB. NADPH oxidasedependent signaling in endothelial cells: role in physiology and pathophysiology. Antioxid Redox Signal 11: 791-810, 2009.
101. Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, Ling L, Worthen GS, and Albelda SM. Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. Cancer Cell 16: 183-194, 2009.
102. Fruehauf JP and Meyskens FL, Jr. Reactive oxygen species: a breath of life or death? Clin Cancer Res 13: 789-794, 2007.
103. Fukumura D, Duda DG, Munn LL, and Jain RK. Tumor microvasculature and microenvironment: novel insights through intravital imaging in pre-clinical models. Microcirculation 17: 206-225, 2010.
104. Funes JM, Quintero M, Henderson S, Martinez D, Qureshi U, Westwood C, Clements MO, Bourboulia D, Pedley RB, Moncada S, and Boshoff C. Transformation of human mesenchymal stem cells increases their dependency on oxidative phosphorylation for energy production. Proc Natl Acad Sci U S A 104: 6223-6228, 2007.
105. Gaengel K, Genove G, Armulik A, and Betsholtz C. Endothelial-mural cell signaling in vascular development and angiogenesis. Arterioscler Thromb Vasc Biol 29: 630-638, 2009.
106. Garrido-Urbani S, Jemelin S, Deffert C, Carnesecchi S, Basset O, Szyndralewiez C, Heitz F, Page P, Montet X, Michalik L, Arbiser J, Ruegg C, Krause KH, and Imhof BA. Targeting vascular NADPH oxidase 1 blocks tumor angiogenesis through a PPARalpha mediated mechanism. PLoS One 6: e14665, 2011.
107. Garzon R, Calin GA, and Croce CM. MicroRNAs in cancer. Annu Rev Med 60: 167-179, 2009.
108. Gatenby RA, Gawlinski ET, Gmitro AF, Kaylor B, and Gillies RJ. Acid-mediated tumor invasion: a multidisciplinary study. Cancer Res 66: 5216-5223, 2006.
109. Giannoni E, Bianchini F, Calorini L, and Chiarugi P. Cancer associated fibroblasts exploit reactive oxygen species through a proinflammatory signature leading to epithelial mesenchymal transition and stemness. Antioxid Redox Signal 14: 2361-2371, 2011.
110. Giembycz MA and Lindsay MA. Pharmacology of the eosinophil. Pharmacol Rev 51: 213-340, 1999.
111. Gius D and Spitz DR. Redox signaling in cancer biology. Antioxid Redox Signal 8: 1249-1252, 2006.
112. Glorieux C, Dejeans N, Sid B, Beck R, Calderon PB, and Verrax J. Catalase overexpression in mammary cancer cells leads to a less aggressive phenotype and an altered response to chemotherapy. Biochem Pharmacol 82: 1384-1390, 2011.
113. Goh J, Enns L, Fatemie S, Hopkins H, Morton J, Pettan-Brewer C, and Ladiges W. Mitochondrial targeted catalase suppresses invasive breast cancer in mice. BMC Cancer 11: 191, 2011.
114. Gordillo G, Fang H, Park H, and Roy S. Nox-4-dependent nuclear H2O2 drives DNA oxidation resulting in 8-OHdG as urinary biomarker and hemangioendothelioma formation. Antioxid Redox Signal 12: 933-943, 2010.
115. Graves JA, Rothermund K, Wang T, Qian W, Van Houten B, and Prochownik EV. Point mutations in c-Myc uncouple neoplastic transformation from multiple other phenotypes in rat fibroblasts. PLoS One 5: e13717, 2010.
116. Gregory AD and Houghton AM. Tumor-associated neutrophils: new targets for cancer therapy. Cancer Res 71: 2411-2416, 2011.
117. Greither T, Wurl P, Grochola L, Bond G, Bache M, Kappler M, Lautenschlager C, Holzhausen HJ, Wach S, Eckert AW, and Taubert H. Expression of microRNA 210 associates with poor survival and age of tumor onset of soft-tissue sarcoma patients. Int J Cancer 130: 1230-1235, 2012.
118. Grek CL and Tew KD. Redox metabolism and malignancy. Curr Opin Pharmacol 10: 362-368, 2010.
119. Hanahan D and Weinberg RA. Hallmarks of cancer: the next generation. Cell 144: 646-674, 2011.
120. Harrison R. Physiological roles of xanthine oxidoreductase. Drug Metab Rev 36: 363-375, 2004.
121. Hashizume H, Baluk P, Morikawa S, McLean JW, Thurston G, Roberge S, Jain RK, and McDonald DM. Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 156: 1363-1380, 2000.
122. Hatfield DL, Yoo MH, Carlson BA, and Gladyshev VN. Selenoproteins that function in cancer prevention and promotion. Biochim Biophys Acta 1790: 1541-1545, 2009.
123. Hayes JD and McMahon M. NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer. Trends Biochem Sci 34: 176-188, 2009.
124. Hogg RT, Thorpe P, and Gerard RD. Retargeting adenoviral vectors to improve gene transfer into tumors. Cancer Gene Ther 18: 275-287, 2011.
125. Hole PS, Pearn L, Tonks AJ, James PE, Burnett AK, Darley RL, and Tonks A. Ras-induced reactive oxygen species promote growth factor-independent proliferation in human CD34 + hematopoietic progenitor cells. Blood 115: 1238-1246, 2010.
126. Honeggar M, Beck R, and Moos PJ. Thioredoxin reductase 1 ablation sensitizes colon cancer cells to methylseleninatemediated cytotoxicity. Toxicol Appl Pharmacol 241: 348-355, 2009.
127. Houghton AM. The paradox of tumor-associated neutrophils: fueling tumor growth with cytotoxic substances. Cell Cycle 9: 1732-1737, 2010.
128. Hsieh CH, Chang HT, Shen WC, Shyu WC, and Liu RS. Imaging the impact of Nox4 in cycling hypoxia-mediated U87 glioblastoma invasion and infiltration. Mol Imaging Biol 14: 489-499, 2012.
129. Hu Y, Rosen DG, Zhou Y, Feng L, Yang G, Liu J, and Huang P. Mitochondrial manganese-superoxide dismutase expression in ovarian cancer: role in cell proliferation and response to oxidative stress. J Biol Chem 280: 39485-39492, 2005.
130. Hurttila H, Koponen JK, Kansanen E, Jyrkkanen HK, Kivela A, Kylatie R, Yla-Herttuala S, and Levonen AL. Oxidative stress-inducible lentiviral vectors for gene therapy. Gene Ther 15: 1271-1279, 2008.
131. Hwang ES and Kim GH. Biomarkers for oxidative stress status of DNA, lipids, and proteins in vitro and in vivo cancer research. Toxicology 229: 1-10, 2007.
132. Hynes RO. The extracellular matrix: not just pretty fibrils. Science 326: 1216-1219, 2009.
133. Ibanez IL, Policastro LL, Tropper I, Bracalente C, Palmieri MA, Rojas PA, Molinari BL, and Duran H. H2O2 scavenging inhibits G1/S transition by increasing nuclear levels of p27KIP1. Cancer Lett 305: 58-68, 2011.
134. Ido A, Uto H, Moriuchi A, Nagata K, Onaga Y, Onaga M, Hori T, Hirono S, Hayashi K, Tamaoki T, and Tsubouchi H. Gene therapy targeting for hepatocellular carcinoma: selective and enhanced suicide gene expression regulated by a hypoxia-inducible enhancer linked to a human alphafetoprotein promoter. Cancer Res 61: 3016-3021, 2001.
135. Indo HP, Davidson M, Yen HC, Suenaga S, Tomita K, Nishii T, Higuchi M, Koga Y, Ozawa T, and Majima HJ. Evidence of ROS generation by mitochondria in cells with impaired electron transport chain and mitochondrial DNA damage. Mitochondrion 7: 106-118, 2007.
136. Irani K, Xia Y, Zweier JL, Sollott SJ, Der CJ, Fearon ER, Sundaresan M, Finkel T, and Goldschmidt-Clermont PJ. Mitogenic signaling mediated by oxidants in Ras-transformed fibroblasts. Science 275: 1649-1652, 1997.
137. Ishikawa K, Takenaga K, Akimoto M, Koshikawa N, Yamaguchi A, Imanishi H, Nakada K, Honma Y, and Hayashi J. ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis. Science 320: 661-664, 2008.
138. Jaruga P, Zastawny TH, Skokowski J, Dizdaroglu M, and Olinski R. Oxidative DNA base damage and antioxidant enzyme activities in human lung cancer. FEBS Lett 341: 59-64, 1994.
139. Jezek P and Plecita-Hlavata L. Mitochondrial reticulum network dynamics in relation to oxidative stress, redox regulation, and hypoxia. Int J Biochem Cell Biol 41: 1790-1804, 2009.
140. Jiang J, Tang YL, and Liang XH. EMT: a new vision of hypoxia promoting cancer progression. Cancer Biol Ther 11: 714-723, 2011.
141. Jiang T, Chen N, Zhao F, Wang XJ, Kong B, Zheng W, and Zhang DD. High levels of Nrf2 determine chemoresistance in type II endometrial cancer. Cancer Res 70: 5486-5496, 2010.
142. Jin C, Rajabi H, and Kufe D. miR-1226 targets expression of the mucin 1 oncoprotein and induces cell death. Int J Oncol 37: 61-69, 2010.
143. Jochems C and Schlom J. Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity. Exp Biol Med (Maywood) 236: 567-579, 2011.
144. Jones RG and Thompson CB. Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Dev 23: 537-548, 2009.
145. Jose C, Bellance N, and Rossignol R. Choosing between glycolysis and oxidative phosphorylation: a tumor's dilemma? Biochim Biophys Acta 1807: 552-561, 2011.
146. Jozkowicz A, Was H, and Dulak J. Heme oxygenase-1 in tumors: is it a false friend? Antioxid Redox Signal 9: 2099-2117, 2007.
147. Kaelin WG, Jr. The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer. Nat Rev Cancer 8: 865-873, 2008.
148. Kaelin WG, Jr., and Ratcliffe PJ. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell 30: 393-402, 2008.
149. Kalinina EV, Chernov NN, and Saprin AN. Involvement of thio-, peroxi-, and glutaredoxins in cellular redox-dependent processes. Biochemistry (Mosc) 73: 1493-1510, 2008.
150. Kamata T. Roles of Nox1 and other Nox isoforms in cancer development. Cancer Sci 100: 1382-1388, 2009.
151. Kamp DW, Shacter E, and Weitzman SA. Chronic inflammation and cancer: the role of the mitochondria. Oncology (Williston Park) 25: 400-410, 413, 2011.
152. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, MacDonald DD, Jin DK, Shido K, Kerns SA, Zhu Z, Hicklin D, Wu Y, Port JL, Altorki N, Port ER, Ruggero D, Shmelkov SV, Jensen KK, Rafii S, and Lyden D. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438: 820-827, 2005.
153. Karihtala P, Kauppila S, Soini Y, and Arja Jukkola V. Oxidative stress and counteracting mechanisms in hormone receptor positive, triple-negative and basal-like breast carcinomas. BMC Cancer 11: 262, 2011.
154. Keith B and Simon MC. Hypoxia-inducible factors, stem cells, and cancer. Cell 129: 465-472, 2007.
155. Kensler TW, Wakabayashi N, and Biswal S. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol 47: 89-116, 2007.
156. Kepp O, Galluzzi L, Lipinski M, Yuan J, and Kroemer G. Cell death assays for drug discovery. Nat Rev Drug Discov 10: 221-237, 2011.
157. Kim HM, Haraguchi N, Ishii H, Ohkuma M, Okano M, Mimori K, Eguchi H, Yamamoto H, Nagano H, Sekimoto M, Doki Y, and Mori M. Increased CD13 Expression reduces reactive oxygen species, promoting survival of liver cancer stem cells via an epithelial-mesenchymal transitionlike phenomenon. Ann Surg Oncol 19: 539-548, 2011.
158. Kim SJ, Miyoshi Y, Taguchi T, Tamaki Y, Nakamura H, Yodoi J, Kato K, and Noguchi S. High thioredoxin expression is associated with resistance to docetaxel in primary breast cancer. Clin Cancer Res 11: 8425-8430, 2005.
159. Kim YR, Eom JI, Kim SJ, Jeung HK, Cheong JW, Kim JS, and Min YH. Myeloperoxidase expression as a potential determinant of parthenolide-induced apoptosis in leukemia bulk and leukemia stem cells. J Pharmacol Exp Ther 335: 389-400, 2010.
160. Kinnula VL and Crapo JD. Superoxide dismutases in malignant cells and human tumors. Free Radic Biol Med 36: 718-744, 2004.
161. Klimova T and Chandel NS. Mitochondrial complex III regulates hypoxic activation of HIF. Cell Death Differ 15: 660-666, 2008.
162. Klotzsch E, Smith ML, Kubow KE, Muntwyler S, Little WC, Beyeler F, Gourdon D, Nelson BJ, and Vogel V. Fibronectin forms the most extensible biological fibers displaying switchable force-exposed cryptic binding sites. Proc Natl Acad Sci U S A 106: 18267-18272, 2009.
163. Kobayashi A, Kang MI, Okawa H, Ohtsuji M, Zenke Y, Chiba T, Igarashi K, and Yamamoto M. Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol Cell Biol 24: 7130-7139, 2004.
164. Kobayashi A, Ohta T, and Yamamoto M. Unique function of the Nrf2-Keap1 pathway in the inducible expression of antioxidant and detoxifying enzymes. Methods Enzymol 378: 273-286, 2004.
165. Kondo S, Toyokuni S, Iwasa Y, Tanaka T, Onodera H, Hiai H, and Imamura M. Persistent oxidative stress in human colorectal carcinoma, but not in adenoma. Free Radic Biol Med 27: 401-410, 1999.
166. Kong Q, Beel JA, and Lillehei KO. A threshold concept for cancer therapy. Med Hypotheses 55: 29-35, 2000.
167. Koppenol WH, Bounds PL, and Dang CV. Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer 11: 325-337, 2011.
168. Kowaltowski AJ, de Souza-Pinto NC, and Castilho RF, Vercesi AE. Mitochondria and reactive oxygen species. Free Radic Biol Med 47: 333-343, 2009.
169. Krishna S, Low IC, and Pervaiz S. Regulation of mitochondrial metabolism: yet another facet in the biology of the oncoprotein Bcl-2. Biochem J 435: 545-551, 2011.
170. Kroemer G and Pouyssegur J. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 13: 472-482, 2008.
171. Kuo HW, Chou SY, Hu TW, Wu FY, and Chen DJ. Urinary 8-hydroxy-2′- deoxyguanosine (8-OHdG) and genetic polymorphisms in breast cancer patients. Mutat Res 631: 62-68, 2007.
172. Ladelfa MF, Toledo MF, Laiseca JE, and Monte M. Interaction of p53 with tumor suppressive and oncogenic signaling pathways to control cellular reactive oxygen species production. Antioxid Redox Signal 15: 1749-1761, 2011.
173. Lambeth JD. NOX enzymes and the biology of reactive oxygen. Nat Rev Immunol 4: 181-189, 2004.
174. Landriscina M, Maddalena F, Laudiero G, and Esposito F. Adaptation to oxidative stress, chemoresistance, and cell survival. Antioxid Redox Signal 11: 2701-2716, 2009.
175. Lardner A. The effects of extracellular pH on immune function. J Leukoc Biol 69: 522-530, 2001.
176. Lau A, Villeneuve NF, Sun Z, Wong PK, and Zhang DD. Dual roles of Nrf2 in cancer. Pharmacol Res 58: 262-270, 2008.
177. Lawenda BD, Kelly KM, Ladas EJ, Sagar SM, Vickers A, and Blumberg JB. Should supplemental antioxidant administration be avoided during chemotherapy
178. Le XF, Merchant O, Bast RC, and Calin GA. The Roles of microRNAs in the cancer invasion-metastasis cascade. Cancer Microenviron 3: 137-147, 2010.
179. Lee JJ, Jacobsen EA, McGarry MP, Schleimer RP, and Lee NA. Eosinophils in health and disease: the LIAR hypothesis. Clin Exp Allergy 40: 563-575, 2010.
180. Lei Y, Huang K, Gao C, Lau QC, Pan H, Xie K, Li J, Liu R, Zhang T, XieN, ShanNai H, Wu H, Zhao X, E CN, Huang C, and Wei Y. Proteomics identification of ITGB3 as a key regulator in ROS-induced migration and invasion of colorectal cancer cells. Mol Cell Proteomics 10: M110.0053972011.
181. Leite de Oliveira R, Hamm A, and Mazzone M. Growing tumor vessels: more than one way to skin a cat -implications for angiogenesis targeted cancer therapies. Mol Aspects Med 32: 71-87, 2011.
182. Levine AJ and Puzio-Kuter AM. The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science 330: 1340-1344, 2010.
183. Li HJ, Everts M, Pereboeva L, Komarova S, Idan A, Curiel DT, and Herschman HR. Adenovirus tumor targeting and hepatic untargeting by a coxsackie/adenovirus receptor ectodomain anti-carcinoembryonic antigen bispecific adapter. Cancer Res 67: 5354-5361, 2007.
184. Li LZ, Zhou R, Xu HN, Moon L, Zhong T, Kim EJ, Qiao H, Reddy R, Leeper D, Chance B, and Glickson JD. Quantitative magnetic resonance and optical imaging biomarkers of melanoma metastatic potential. Proc Natl Acad Sci U S A 106: 6608-6613, 2009.
185. Li Z and Rich JN. Hypoxia and hypoxia inducible factors in cancer stem cell maintenance. Curr Top Microbiol Immunol 345: 21-30, 2010.
186. Limon-Pacheco J and Gonsebatt ME. The role of antioxidants and antioxidant-related enzymes in protective responses to environmentally induced oxidative stress. Mutat Res 674: 137-147, 2009.
187. Lisanti MP, Martinez-Outschoorn UE, Chiavarina B, Pavlides S, Whitaker-Menezes D, Tsirigos A, Witkiewicz A, Lin Z, Balliet R, Howell A, and Sotgia F. Understanding the "lethal" drivers of tumor-stroma co-evolution: emerging role(s) for hypoxia, oxidative stress and autophagy/mitophagy in the tumor micro-environment. Cancer Biol Ther 10: 537-542, 2010.
188. Liu J, Cao L, Chen J, Song S, Lee IH, Quijano C, Liu H, Keyvanfar K, Chen H, Cao LY, Ahn BH, Kumar NG, Rovira, II, Xu XL, van Lohuizen M, Motoyama N, Deng CX, and Finkel T. Bmi1 regulates mitochondrial function and the DNA damage response pathway. Nature 459: 387-392, 2009.
189. Liu J, Du J, Zhang Y, Sun W, Smith BJ, Oberley LW, and Cullen JJ. Suppression of the malignant phenotype in pancreatic cancer by overexpression of phospholipid hydroperoxide glutathione peroxidase. Hum Gene Ther 17: 105-116, 2006.
190. Liu J, Hinkhouse MM, Sun W, Weydert CJ, Ritchie JM, Oberley LW, and Cullen JJ. Redox regulation of pancreatic cancer cell growth: role of glutathione peroxidase in the suppression of the malignant phenotype. Hum Gene Ther 15: 239-250, 2004.
191. Llera AS, Girotti MR, Benedetti LG and Podhajcer OL. Matricellular proteins and inflammatory cells: a task force to promote or defeat cancer? Cytokine Growth Factor Rev 21: 67-76, 2010.
192. Lopez CA, Kimchi ET, Mauceri HJ, Park JO, Mehta N, Murphy KT, Beckett MA, Hellman S, Posner MC, Kufe DW, and Weichselbaum RR. Chemoinducible gene therapy: a strategy to enhance doxorubicin antitumor activity. Mol Cancer Ther 3: 1167-1175, 2004.
193. Lopez-Lazaro M. Excessive superoxide anion generation plays a key role in carcinogenesis. Int J Cancer 120: 1378-1380, 2007.
194. Lu JM, Lin PH, Yao Q, and Chen C. Chemical and molecular mechanisms of antioxidants: experimental approaches and model systems. J Cell Mol Med 14: 840-860, 2010.
195. Lu X and Kang Y. Hypoxia and hypoxia-inducible factors: master regulators of metastasis. Clin Cancer Res 16: 5928-5935, 2010.
196. Lu Y and Madu CO. Viral-based gene delivery and regulated gene expression for targeted cancer therapy. Expert Opin Drug Deliv 7: 19-35, 2010.
197. Ma D, Warabi E, Yanagawa T, Kimura S, Harada H, Yamagata K, and Ishii T. Peroxiredoxin I plays a protective role against cisplatin cytotoxicity through mitogen activated kinase signals. Oral Oncol 45: 1037-1043, 2009.
198. Ma Y, Aymeric L, Locher C, Kroemer G, and Zitvogel L. The dendritic cell-tumor cross-talk in cancer. Curr Opin Immunol 23: 146-152, 2011.
199. Maciag A, Sithanandam G, and Anderson LM. Mutant KrasV12 increases COX-2, peroxides and DNA damage in lung cells. Carcinogenesis 25: 2231-2237, 2004.
200. Majmundar AJ, Wong WJ, and Simon MC. Hypoxiainducible factors and the response to hypoxic stress. Mol Cell 40: 294-309, 2010.
201. Maltby S, Khazaie K, and McNagny KM. Mast cells in tumor growth: angiogenesis, tissue remodelling and immune-modulation. Biochim Biophys Acta 1796: 19-26, 2009.
202. Mannello F. What does matrix metalloproteinase-1 expression in patients with breast cancer really tell us? BMC Med 9: 95, 2011.
203. Mannello F, Medda V, and Tonti GA. Hypoxia and neural stem cells: from invertebrates to brain cancer stem cells. Int J Dev Biol 55: 569-581, 2011.
204. Mannello F, Qin W, Zhu W, Fabbri L, Tonti GA, and Sauter ER. Nipple aspirate fluids from women with breast cancer contain increased levels of group IIa secretory phospholipase A2. Breast Cancer Res Treat 111: 209-218, 2008.
205. Mannello F, Tonti GA, and Medda V. Protein oxidation in breast microenvironment: nipple aspirate fluid collected from breast cancer women contains increased protein carbonyl concentration. Cell Oncol 31: 383-392, 2009.
206. Mannello F, Tonti GA, Pederzoli A, Simone P, Smaniotto A, and Medda V. Detection of superoxide dismutase-1 in nipple aspirate fluids: a reactive oxygen species-regulating enzyme in the breast cancer microenvironment. Clin Breast Cancer 10: 238-45, 2010.
207. Mantovani A, Savino B, Locati M, Zammataro L, Allavena P, and Bonecchi R. The chemokine system in cancer biology and therapy. Cytokine Growth Factor Rev 21: 27-39, 2010.
208. Mantovani A, Sozzani S, Locati M, Allavena P, and Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23: 549-555, 2002.
209. Martinez-Outschoorn UE, Balliet RM, Rivadeneira DB, Chiavarina B, Pavlides S, Wang C, Whitaker-Menezes D, Daumer KM, Lin Z, Witkiewicz AK, Flomenberg N, Howell A, Pestell RG, Knudsen ES, Sotgia F, and Lisanti MP. Oxidative stress in cancer associated fibroblasts drives tumor-stroma co-evolution: a new paradigm for understanding tumor metabolism, the field effect and genomic instability in cancer cells. Cell Cycle 9: 3256-3276, 2010.
210. Martinez-Outschoorn UE, Trimmer C, Lin Z, Whitaker-Menezes D, Chiavarina B, Zhou J, Wang C, Pavlides S, Martinez-Cantarin MP, Capozza F, Witkiewicz AK, Flomenberg N, Howell A, Pestell RG, Caro J, Lisanti MP, and Sotgia F. Autophagy in cancer associated fibroblasts promotes tumor cell survival: role of hypoxia, HIF1 induction and NFkappaB activation in the tumor stromal microenvironment. Cell Cycle 9: 3515-3533, 2010.
211. Mathew R and White E. Autophagy in tumorigenesis and energy metabolism: friend by day, foe by night. Curr Opin Genet Dev 21: 113-119, 2011.
212. Matsumoto S, Yasui H, Mitchell JB, and Krishna MC. Imaging cycling tumor hypoxia. Cancer Res 70: 10019-10023, 2010.
213. Mazumdar J, Dondeti V, and Simon MC. Hypoxia-inducible factors in stem cells and cancer. J Cell Mol Med 13: 4319-4328, 2009.
214. Mazurek S, Boschek CB, Hugo F, and Eigenbrodt E. Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin Cancer Biol 15: 300-308, 2005.
215. Meyer Y, Buchanan BB, Vignols F, and Reichheld JP. Thioredoxins and glutaredoxins: unifying elements in redox biology. Annu Rev Genet 43: 335-367, 2009.
216. Miller TW, Isenberg JS, and Roberts DD. Molecular regulation of tumor angiogenesis and perfusion via redox signaling. Chem Rev 109: 3099-3124, 2009.
217. Min JY, Lim SO, and Jung G. Downregulation of catalase by reactive oxygen species via hypermethylation of CpG island II on the catalase promoter. FEBS Lett 584: 2427-2432, 2010.
218. Mochizuki T, Furuta S, Mitsushita J, Shang WH, Ito M, Yokoo Y, Yamaura M, Ishizone S, Nakayama J, Konagai A, Hirose K, Kiyosawa K, and Kamata T. Inhibition of NADPH oxidase 4 activates apoptosis via the AKT/ apoptosis signal-regulating kinase 1 pathway in pancreatic cancer PANC-1 cells. Oncogene 25: 3699-3707, 2006.
219. Mohyeldin A, Garzon-Muvdi T, and Quinones-Hinojosa A. Oxygen in stem cell biology: a critical component of the stem cell niche. Cell Stem Cell 7: 150-161, 2010.
220. Morabito F, Cristani M, Saija A, Stelitano C, Callea V, Tomaino A, Minciullo PL, and Gangemi S. Lipid peroxidation and protein oxidation in patients affected by Hodgkin's lymphoma. Mediators Inflamm 13: 381-383, 2004.
221. Moreno-Sanchez R, Rodriguez-Enriquez S, Saavedra E, Marin-Hernandez A, and Gallardo-Perez JC. The bioenergetics of cancer: is glycolysis the main ATP supplier in all tumor cells? Biofactors 35: 209-225, 2009.
222. Morgan D, Cherny VV, Murphy R, Katz BZ, and De-Coursey TE. The pH dependence of NADPH oxidase in human eosinophils. J Physiol 569: 419-431, 2005.
223. Morikawa S, Baluk P, Kaidoh T, Haskell A, Jain RK, and McDonald DM. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol 160: 985-1000, 2002.
224. Murakami A and Ohigashi H. Targeting NOX, INOS and COX-2 in inflammatory cells: chemoprevention using food phytochemicals. Int J Cancer 121: 2357-2363, 2007.
225. Mytar B, Woloszyn M, Macura-Biegun A, Hajto B, Ruggiero I, Piekarska B, and Zembala M. Involvement of pattern recognition receptors in the induction of cytokines and reactive oxygen intermediates production by human monocytes/macrophages stimulated with tumour cells. Anticancer Res 24: 2287-2293, 2004.
226. Nagaraj S and Gabrilovich DI. Tumor escape mechanism governed by myeloid-derived suppressor cells. Cancer Res 68: 2561-2563, 2008.
227. Naiki-Ito A, Asamoto M, Hokaiwado N, Takahashi S, Yamashita H, Tsuda H, Ogawa K, and Shirai T. Gpx2 is an overexpressed gene in rat breast cancers induced by three different chemical carcinogens. Cancer Res 67: 11353-11358, 2007.
228. Neumann CA and Fang Q. Are peroxiredoxins tumor suppressors? Curr Opin Pharmacol 7: 375-380, 2007.
229. Niture SK and Jaiswal AK. Nrf2 protein up-regulates antiapoptotic protein Bcl-2 and prevents cellular apoptosis. J Biol Chem 287: 9873-9886, 2012.
230. Oberley LW. Mechanism of the tumor suppressive effect of MnSOD overexpression. Biomed Pharmacother 59: 143-148, 2005.
231. Oberley LW and Buettner GR. Role of superoxide dismutase in cancer: a review. Cancer Res 39: 1141-1149, 1979.
232. Oldberg A, Kalamajski S, Salnikov AV, Stuhr L, Morgelin M, Reed RK, Heldin NE, and Rubin K. Collagen-binding proteoglycan fibromodulin can determine stroma matrix structure and fluid balance in experimental carcinoma. Proc Natl Acad Sci U S A 104: 13966-13971, 2007.
233. Onumah OE, Jules GE, Zhao Y, Zhou L, Yang H, and Guo Z. Overexpression of catalase delays G0/G1-to S-phase transition during cell cycle progression in mouse aortic endothelial cells. Free Radic Biol Med 46: 1658-1667, 2009.
234. Ostrand-Rosenberg S and Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 182: 4499-4506, 2009.
235. Ozben T. Oxidative stress and apoptosis: impact on cancer therapy. J Pharm Sci 96: 2181-2196, 2007.
236. Pani G, Galeotti T, and Chiarugi P. Metastasis: cancer cell's escape from oxidative stress. Cancer Metastasis Rev 29: 351-378, 2010.
237. Pani G, Giannoni E, Galeotti T, and Chiarugi P. Redoxbased escape mechanism from death: the cancer lesson. Antioxid Redox Signal 11: 2791-2806, 2009.
238. Papp LV, Lu J, Holmgren A, and Khanna KK. From selenium to selenoproteins: synthesis, identity, and their role in human health. Antioxid Redox Signal 9: 775-806, 2007.
239. Park JJ, Chang HW, Jeong EJ, Roh JL, Choi SH, Jeon SY, Ko GH, and Kim SY. Peroxiredoxin IV protects cells from radiation-induced apoptosis in head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 73: 1196-1202, 2009.
240. Parks SK, Chiche J, and Pouyssegur J. pH control mechanisms of tumor survival and growth. J Cell Physiol 226: 299-308, 2011.
241. Pasqualini R, Arap W, and McDonald DM. Probing the structural and molecular diversity of tumor vasculature. Trends Mol Med 8: 563-571, 2002.
242. Perumal SS, Shanthi P, and Sachdanandam P. Combined efficacy of tamoxifen and coenzyme Q10 on the status of lipid peroxidation and antioxidants in DMBA induced breast cancer. Mol Cell Biochem 273: 151-160, 2005.
243. Phang JM, Pandhare J, Zabirnyk O, and Liu Y. PPARgamma and proline oxidase in cancer. PPAR Res 2008: 542694, 2008.
244. Pietras K and Ostman A. Hallmarks of cancer: interactions with the tumor stroma. Exp Cell Res 316: 1324-1331, 2010.
245. Ping YF and Bian XW. Cancer stem cells switch on tumor neovascularization. Curr Mol Med 11: 69-75, 2011.
246. Pizzo AM, Kokini K, Vaughn LC, Waisner BZ, and Voytik-Harbin SL. Extracellular matrix (ECM) microstructural composition regulates local cell-ECM biomechanics and fundamental fibroblast behavior: a multidimensional perspective. J Appl Physiol 98: 1909-1921, 2005.
247. Poerschke RL and Moos PJ. Thioredoxin reductase 1 knockdown enhances selenazolidine cytotoxicity in human lung cancer cells via mitochondrial dysfunction. Biochem Pharmacol 81: 211-221, 2011.
248. Policastro L, Molinari B, Larcher F, Blanco P, Podhajcer OL, Costa CS, Rojas P, and Duran H. Imbalance of antioxidant enzymes in tumor cells and inhibition of proliferation and malignant features by scavenging hydrogen peroxide. Mol Carcinog 39: 103-113, 2004.
249. Policastro LL, Ibanez IL, Duran HA, Soria G, Gottifredi V, and Podhajcer OL. Suppression of cancer growth by nonviral gene therapy based on a novel reactive oxygen species-responsive promoter. Mol Ther 17: 1355-1364, 2009.
250. Pries AR, Cornelissen AJ, Sloot AA, Hinkeldey M, Dreher MR, Hopfner M, Dewhirst MW, and Secomb TW. Structural adaptation and heterogeneity of normal and tumor microvascular networks. PLoS Comput Biol 5: e1000394, 2009.
251. Provenzano PP, Inman DR, Eliceiri KW, Knittel JG, Yan L, Rueden CT, White JG, and Keely PJ. Collagen density promotes mammary tumor initiation and progression. BMC Med 6: 11, 2008.
252. Prow T, Grebe R, Merges C, Smith JN, McLeod DS, Leary JF, and Lutty GA. Nanoparticle tethered antioxidant response element as a biosensor for oxygen induced toxicity in retinal endothelial cells. Mol Vis 12: 616-625, 2006.
253. Puzio-Kuter AM. The role of p53 in metabolic regulation. Genes Cancer 2: 385-391, 2011.
254. Qu Y, Wang J, Ray PS, Guo H, Huang J, Shin-Sim M, Bukoye BA, Liu B, Lee AV, Lin X, Huang P, Martens JW, Giuliano AE, Zhang N, Cheng NH, and Cui X. Thioredoxin-like 2 regulates human cancer cell growth and metastasis via redox homeostasis and NF-kappaB signaling. J Clin Invest 121: 212-225, 2011.
255. Qu Y, Zhao S, Hong J, and Tang S. Radiosensitive gene therapy through imRNA expression for silencing manganese superoxide dismutase. J Cancer Res Clin Oncol 136: 953-959, 2010.
256. Rabinowitz JD and White E. Autophagy and metabolism. Science 330: 1344-1348, 2010.
257. Radisky DC, Levy DD, Littlepage LE, Liu H, Nelson CM, Fata JE, Leake D, Godden EL, Albertson DG, Nieto MA, Werb Z, and Bissell MJ. Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature 436: 123-127, 2005.
258. Rafii S, Heissig B, and Hattori K. Efficient mobilization and recruitment of marrow-derived endothelial and hematopoietic stem cells by adenoviral vectors expressing angiogenic factors. Gene Ther 9: 631-641, 2002.
259. Raica M, Cimpean AM, and Ribatti D. Angiogenesis in premalignant conditions. Eur J Cancer 45: 1924-1934, 2009.
260. Raimundo N, Baysal BE, and Shadel GS. Revisiting the TCA cycle: signaling to tumor formation. Trends Mol Med 17: 641-649, 2012.
261. Raj L, Ide T, Gurkar AU, Foley M, Schenone M, Li X, Tolliday NJ, Golub TR, Carr SA, Shamji AF, Stern AM, Mandinova A, Schreiber SL, and Lee SW. Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature 475: 231-234, 2011.
262. Ralph SJ, Rodriguez-Enriquez S, Neuzil J, Saavedra E, and Moreno-Sanchez R. The causes of cancer revisited: "mitochondrial malignancy" and ROS-induced oncogenic transformation -why mitochondria are targets for cancer therapy. Mol Aspects Med 31: 145-170, 2010.
263. Rankin EB and Giaccia AJ. The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ 15: 678-685, 2008.
264. Rao Gogineni V, Kumar Nalla A, Gupta R, Gorantla B, Gujrati M, Dinh DH, and Rao JS. Radiation-inducible silencing of uPA and uPAR in vitro and in vivo in meningioma. Int J Oncol 36: 809-816, 2010.
265. Ravi D, Muniyappa H, and Das KC. Endogenous thioredoxin is required for redox cycling of anthracyclines and p53-dependent apoptosis in cancer cells. J Biol Chem 280: 40084-40096, 2005.
266. Ray R and Shah AM. NADPH oxidase and endothelial cell function. Clin Sci (Lond) 109: 217-226, 2005.
267. Reddy NM, Kleeberger SR, Bream JH, Fallon PG, Kensler TW, Yamamoto M, and Reddy SP. Genetic disruption of the Nrf2 compromises cell-cycle progression by impairing GSH-induced redox signaling. Oncogene 27: 5821-5832, 2008.
268. Rhee SG, Bae YS, Lee SR, and Kwon J. Hydrogen peroxide: a key messenger that modulates protein phosphorylation through cysteine oxidation. Sci STKE 2000: pe1, 2000.
269. Riemann A, Schneider B, Ihling A, Nowak M, Sauvant C, Thews O, and Gekle M. Acidic environment leads to ROSinduced MAPK signaling in cancer cells. PLoS One 6: e22445, 2011.
270. Saga Y, Ohwada M, Suzuki M, Konno R, Kigawa J, Ueno S, and Mano H. Glutathione peroxidase 3 is a candidate mechanism of anticancer drug resistance of ovarian clear cell adenocarcinoma. Oncol Rep 20: 1299-1303, 2008.
271. Samant RS and Shevde LA. Recent advances in antiangiogenic therapy of cancer. Oncotarget 2: 122-134, 2011.
272. Sampson N, Koziel R, Zenzmaier C, Bubendorf L, Plas E, Jansen-Durr P, and Berger P. ROS signaling by NOX4 drives fibroblast-to-myofibroblast differentiation in the diseased prostatic stroma. Mol Endocrinol 25: 503-515, 2011.
273. Sarsour EH, Kumar MG, Chaudhuri L, Kalen AL, and Goswami PC. Redox control of the cell cycle in health and disease. Antioxid Redox Signal 11: 2985-3011, 2009.
274. Scherz-Shouval R and Elazar Z. Regulation of autophagy by ROS: physiology and pathology. Trends Biochem Sci 36: 30-38, 2011.
275. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3: 721-732, 2003.
276. Sharma A, Li X, Bangari DS, and Mittal SK. Adenovirus receptors and their implications in gene delivery. Virus Res 143: 184-194, 2009.
277. Shlomai J. Redox control of protein-DNA interactions: from molecular mechanisms to significance in signal transduction, gene expression, and DNA replication. Antioxid Redox Signal 13: 1429-1476, 2010.
278. Shoshan-Barmatz V, De Pinto V, Zweckstetter M, Raviv Z, Keinan N, and Arbel N. VDAC, a multi-functional mitochondrial protein regulating cell life and death. Mol Aspects Med 31: 227-285, 2010.
279. Sica A. Role of tumour-associated macrophages in cancerrelated inflammation. Exp Oncol 32: 153-158, 2010.
280. Sica A, Larghi P, Mancino A, Rubino L, Porta C, Totaro MG, Rimoldi M, Biswas SK, Allavena P, and Mantovani A. Macrophage polarization in tumour progression. Semin Cancer Biol 18: 349-355, 2008.
281. Sims GP, Rowe DC, Rietdijk ST, Herbst R, and Coyle AJ. HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol 28: 367-388, 2010.
282. Singh A, Boldin-Adamsky S, Thimmulappa RK, Rath SK, Ashush H, Coulter J, Blackford A, Goodman SN, Bunz F, Watson WH, Gabrielson E, Feinstein E, and Biswal S. RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy. Cancer Res 68: 7975-7984, 2008.
283. Smolkova K, Plecita-Hlavata L, Bellance N, Benard G, Rossignol R, and Jezek P. Waves of gene regulation suppress and then restore oxidative phosphorylation in cancer cells. Int J Biochem Cell Biol 43: 950-968.
284. Soini Y, Kahlos K, Napankangas U, Kaarteenaho-Wiik R, Saily M, Koistinen P, Paaakko P, Holmgren A, and Kinnula VL. Widespread expression of thioredoxin and thioredoxin reductase in non-small cell lung carcinoma. Clin Cancer Res 7: 1750-1757, 2001.
285. Solaini G, Baracca A, Lenaz G, and Sgarbi G. Hypoxia and mitochondrial oxidative metabolism. Biochim Biophys Acta 1797: 1171-1177, 2010.
286. Sotgia F, Martinez-Outschoorn UE, and Lisanti MP. Mitochondrial oxidative stress drives tumor progression and metastasis: should we use antioxidants as a key component of cancer treatment and prevention? BMC Med 9: 62, 2011.
287. St-Pierre J, Buckingham JA, Roebuck SJ, and Brand MD. Topology of superoxide production from different sites in the mitochondrial electron transport chain. J Biol Chem 277: 44784-44790, 2002.
288. Stone JR and Yang S. Hydrogen peroxide: a signaling messenger. Antioxid Redox Signal 8: 243-270, 2006.
289. Swietach P, Hulikova A, Vaughan-Jones RD, and Harris AL. New insights into the physiological role of carbonic anhydrase IX in tumour pH regulation. Oncogene 29: 6509-6521, 2010.
290. Szatrowski TP and Nathan CF. Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res 51: 794-798, 1991.
291. Taddei ML, Parri M, Mello T, Catalano A, Levine AD, Raugei G, Ramponi G, and Chiarugi P. Integrin-mediated cell adhesion and spreading engage different sources of reactive oxygen species. Antioxid Redox Signal 9: 469-481, 2007.
292. Taguchi K, Motohashi H, and Yamamoto M. Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution. Genes Cells 16: 123-140, 2011.
293. Tang D, Kang R, Zeh HJ, 3rd, and Lotze MT. High-mobility group box 1 and cancer. Biochim Biophys Acta 1799: 131-140, 2010.
294. Tang D, Kang R, Zeh HJ, 3rd, and Lotze MT. High-mobility group box 1, oxidative stress, and disease. Antioxid Redox Signal 14: 1315-1335, 2011.
295. Teoh ML, Fitzgerald MP, Oberley LW, and Domann FE. Overexpression of extracellular superoxide dismutase attenuates heparanase expression and inhibits breast carcinoma cell growth and invasion. Cancer Res 69: 6355-6363, 2009.
296. Teoh ML, Sun W, Smith BJ, Oberley LW, and Cullen JJ. Modulation of reactive oxygen species in pancreatic cancer. Clin Cancer Res 13: 7441-7450, 2007.
297. Thapa D and Ghosh R. Antioxidants for prostate cancer chemoprevention: challenges and opportunities. Biochem Pharmacol 83: 1319-1330, 2012.
298. Thomlinson RH and Gray LH. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 9: 539-549, 1955.
299. Tlsty TD and Coussens LM. Tumor stroma and regulation of cancer development. Annu Rev Pathol 1: 119-150, 2006.
300. Toppo S, Flohe L, Ursini F, Vanin S, and Maiorino M. Catalytic mechanisms and specificities of glutathione peroxidases: variations of a basic scheme. Biochim Biophys Acta 1790: 1486-1500, 2009.
301. Toyokuni S, Okamoto K, Yodoi J, and Hiai H. Persistent oxidative stress in cancer. FEBS Lett 358: 1-3, 1995.
302. Trachootham D, Alexandre J, and Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov 8: 579-591, 2009.
303. Trimmer C, Sotgia F, Whitaker-Menezes D, Balliet RM, Eaton G, Martinez-Outschoorn UE, Pavlides S, Howell A, Iozzo RV, Pestell RG, Scherer PE, Capozza F, and Lisanti MP. Caveolin-1 and mitochondrial SOD2 (MnSOD) function as tumor suppressors in the stromal microenvironment: a new genetically tractable model for human cancer associated fibroblasts. Cancer Biol Ther 11: 383-394, 2011.
304. Tu BP, and Weissman JS. Oxidative protein folding in eukaryotes: mechanisms and consequences. J Cell Biol 164: 341-346, 2004.
305. Tuzgen S, Hanimoglu H, Tanriverdi T, Kacira T, Sanus GZ, Atukeren P, Dashti R, Gumustas K, Canbaz B, and Kaynar MY. Relationship between DNA damage and total antioxidant capacity in patients with glioblastoma multiforme. Clin Oncol (R Coll Radiol) 19: 177-181, 2007.
306. Ueta E, Yoneda K, Kimura T, Tatemoto Y, Doi S, Yamamoto T, and Osaki T. Mn-SOD antisense upregulates in vivo apoptosis of squamous cell carcinoma cells by anticancer drugs and gamma-rays regulating expression of the BCL-2 family proteins, COX-2 and p21. Int J Cancer 94: 545-550, 2001.
307. Ungerstedt JS, Sowa Y, Xu WS, Shao Y, Dokmanovic M, Perez G, Ngo L, Holmgren A, Jiang X, and Marks PA. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci U S A 102: 673-678, 2005.
308. Ushio-Fukai M. Redox signaling in angiogenesis: role of NADPH oxidase. Cardiovasc Res 71: 226-235, 2006.
309. Ushio-Fukai M and Nakamura Y. Reactive oxygen species and angiogenesis: NADPH oxidase as target for cancer therapy. Cancer Lett 266: 37-52, 2008.
310. Ushio-Fukai M and Urao N. Novel role of NADPH oxidase in angiogenesis and stem/progenitor cell function. Antioxid Redox Signal 11: 2517-2533, 2009.
311. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, and Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 39: 44-84, 2007.
312. Vaupel P. Hypoxia and aggressive tumor phenotype: implications for therapy and prognosis. Oncologist 13 Suppl 3: 21-26, 2008.
313. Venkataraman S, Alimova I, Fan R, Harris P, Foreman N, and Vibhakar R. MicroRNA 128a increases intracellular ROS level by targeting Bmi-1 and inhibits medulloblastoma cancer cell growth by promoting senescence. PLoS One 5: e10748, 2010.
314. Verschoor ML, Wilson LA, and Singh G. Mechanisms associated with mitochondrial-generated reactive oxygen species in cancer. Can J Physiol Pharmacol 88: 204-219, 2010.
315. Vivas-Mejia PE, Ozpolat B, Chen X, and Lopez-Berestein G. Downregulation of the c-MYC target gene, peroxiredoxin III, contributes to arsenic trioxide-induced apoptosis in acute promyelocytic leukemia. Int J Cancer 125: 264-275, 2009.
316. Voss MJ, Niggemann B, Zanker KS, and Entschladen F. Tumour reactions to hypoxia. Curr Mol Med 10: 381-386, 2010.
317. Walsh B, Pearl A, Suchy S, Tartaglio J, Visco K, and Phelan SA. Overexpression of Prdx6 and resistance to peroxideinduced death in Hepa1-6 cells: Prdx suppression increases apoptosis. Redox Rep 14: 275-284, 2009.
318. Wang C, Song B, Song W, Liu J, Sun A, Wu D, Yu H, Lian J, Chen L, and Han J. Underexpressed microRNA-199b-5p targets hypoxia-inducible factor-1alpha in hepatocellular carcinoma and predicts prognosis of hepatocellular carcinoma patients. J Gastroenterol Hepatol 26: 1630-1637, 2011.
319. Wang J and Yi J. Cancer cell killing via ROS: to increase or decrease, that is the question. Cancer Biol Ther 7: 1875-1884, 2008.
320. Wang T, Tamae D, LeBon T, Shively JE, Yen Y, and Li JJ. The role of peroxiredoxin II in radiation-resistant MCF-7 breast cancer cells. Cancer Res 65: 10338-10346, 2005.
321. Warburg O. On the origin of cancer cells. Science 123: 309-314, 1956.
322. Waypa GB, Marks JD, Guzy R, Mungai PT, Schriewer J, Dokic D, and Schumacker PT. Hypoxia triggers subcellular compartmental redox signaling in vascular smooth muscle cells. Circ Res 106: 526-535, 2010.
323. Weinberg F and Chandel NS. Reactive oxygen species-dependent signaling regulates cancer. Cell Mol Life Sci 66: 3663-3673, 2009.
324. Weinberg F, Hamanaka R, Wheaton WW, Weinberg S, Joseph J, Lopez M, Kalyanaraman B, Mutlu GM, Budinger GR, and Chandel NS. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc Natl Acad Sci U S A 107: 8788-8793, 2010.
325. Weir B, Zhao X, and Meyerson M. Somatic alterations in the human cancer genome. Cancer Cell 6: 433-438, 2004.
326. Wenger RH, Stiehl DP, and Camenisch G. Integration of oxygen signaling at the consensus HRE. Sci STKE 2005: re12, 2005.
327. Werner E and Werb Z. Integrins engage mitochondrial function for signal transduction by a mechanism dependent on Rho GTPases. J Cell Biol 158: 357-368, 2002.
328. Weydert CJ, Zhang Y, Sun W, Waugh TA, Teoh ML, Andringa KK, Aykin-Burns N, Spitz DR, Smith BJ, and Oberley LW. Increased oxidative stress created by adenoviral MnSOD or CuZnSOD plus BCNU (1,3-bis(2-chloroethyl)-1-nitrosourea) inhibits breast cancer cell growth. Free Radic Biol Med 44: 856-867, 2008.
329. Wilson A and Trumpp A. Bone-marrow haematopoieticstem-cell niches. Nat Rev Immunol 6: 93-106, 2006.
330. Wilson WR and Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer 11: 393-410, 2011.
331. Wood ZA, Schroder E, Robin Harris J, and Poole LB. Structure, mechanism and regulation of peroxiredoxins. Trends Biochem Sci 28: 32-40, 2003.
332. Wu RF and Terada LS. Ras and Nox: linked signaling networks? Free Radic Biol Med 47: 1276-1281, 2009.
333. Xing F, Saidou J, and Watabe K. Cancer associated fibroblasts (CAFs) in tumor microenvironment. Front Biosci 15: 166-179, 2010.
334. Xiong J, Sun WJ, Wang WF, Liao ZK, Zhou FX, Kong HY, Xu Y, Xie CH, and Zhou YF. Novel, chimeric, cancer-specific, and radiation-inducible gene promoters for suicide gene therapy of cancer. Cancer 118: 536-548, 2012.
335. Xouri G and Christian S. Origin and function of tumor stroma fibroblasts. Semin Cell Dev Biol 21: 40-46, 2010.
336. Xu HN, Nioka S, Glickson JD, Chance B, and Li LZ. Quantitative mitochondrial redox imaging of breast cancer metastatic potential. J Biomed Opt 15: 036010, 2010.
337. Xu Y, Fang F, Zhang J, Josson S, St. Clair WH, and St. Clair DK. miR-17* suppresses tumorigenicity of prostate cancer by inhibiting mitochondrial antioxidant enzymes. PLoS One 5: e14356, 2010.
338. Yamakuchi M, Yagi S, Ito T, and Lowenstein CJ. Micro-RNA-22 regulates hypoxia signaling in colon cancer cells. PLoS One 6: e20291, 2011.
339. Yang Y, Tian Y, Yan C, Jin X, Tang J, and Shen X. Determinants of urinary 8-hydroxy-2′-deoxyguanosine in Chinese children with acute leukemia. Environ Toxicol 24: 446-452, 2009.
340. Ye XQ, Li Q, Wang GH, Sun FF, Huang GJ, Bian XW, Yu SC, and Qian GS. Mitochondrial and energy metabolismrelated properties as novel indicators of lung cancer stem cells. Int J Cancer 129: 820-831, 2011.
341. Yeh CC, Hou MF, Tsai SM, Lin SK, Hsiao JK, Huang JC, Wang LH, Wu SH, Hou LA, Ma H, and Tsai LY. Superoxide anion radical, lipid peroxides and antioxidant status in the blood of patients with breast cancer. Clin Chim Acta 361: 104-111, 2005.
342. Yeung BH, Wong KY, Lin MC, Wong CK, Mashima T, Tsuruo T, and Wong AS. Chemosensitisation by manganese superoxide dismutase inhibition is caspase-9 dependent and involves extracellular signal-regulated kinase 1/2. Br J Cancer 99: 283-293, 2008.
343. Yoo MH, Xu XM, Carlson BA, Patterson AD, Gladyshev VN, and Hatfield DL. Targeting thioredoxin reductase 1 reduction in cancer cells inhibits self-sufficient growth and DNA replication. PLoS One 2: e1112, 2007.
344. Zabirnyk O, Liu W, Khalil S, Sharma A, and Phang JM. Oxidized low-density lipoproteins upregulate proline oxidase to initiate ROS-dependent autophagy. Carcinogenesis 31: 446-454, 2010.
345. Zangar RC, Davydov DR, and Verma S. Mechanisms that regulate production of reactive oxygen species by cytochrome P450. Toxicol Appl Pharmacol 199: 316-331, 2004.
346. Zhang B, Wang Y, Liu K, Yang X, Song M, and Bai Y. Adenovirus-mediated transfer of siRNA against peroxiredoxin I enhances the radiosensitivity of human intestinal cancer. Biochem Pharmacol 75: 660-667, 2008.
347. Zhang B, Wang Y, and Su Y. Peroxiredoxins, a novel target in cancer radiotherapy. Cancer Lett 286: 154-160, 2009.
348. Zhang DD. Mechanistic studies of the Nrf2-Keap1 signaling pathway. Drug Metab Rev 38: 769-789, 2006.
349. Zhang L, Wu YD, Li P, Tu J, Niu YL, Xu CM, and Zhang ST. Effects of cyclooxygenase-2 on human esophageal squamous cell carcinoma. World J Gastroenterol 17: 4572-4580, 2011.
350. Zhang X, Zheng Y, Fried LE, Du Y, Montano SJ, Sohn A, Lefkove B, Holmgren L, Arbiser JL, Holmgren A, and Lu J. Disruption of the mitochondrial thioredoxin system as a cell death mechanism of cationic triphenylmethanes. Free Radic Biol Med 50: 811-820, 2011.
351. Zhang Y, Du Y, Le W, Wang K, Kieffer N, and Zhang J. Redox control of the survival of healthy and diseased cells. Antioxid Redox Signal, 15: 2867-2908, 2011.
352. Zhang Y, Gu J, Zhao L, He L, Qian W, Wang J, Wang Y, Qian Q, Qian C, Wu J, and Liu XY. Complete elimination of colorectal tumor xenograft by combined manganese superoxide dismutase with tumor necrosis factor-related apoptosis-inducing ligand gene virotherapy. Cancer Res 66: 4291-4298, 2006.
353. Zhong L, D'Urso A, Toiber D, Sebastian C, Henry RE, Vadysirisack DD, Guimaraes A, Marinelli B, Wikstrom JD, Nir T, Clish CB, Vaitheesvaran B, Iliopoulos O, Kurland I, Dor Y, Weissleder R, Shirihai OS, Ellisen LW, Espinosa JM, and Mostoslavsky R. The histone deacetylase Sirt6 regulates glucose homeostasis via Hif1alpha. Cell 140: 280-293, 2010.
354. Zielske SP, Spalding AC, Wicha MS, and Lawrence TS. Ablation of breast cancer stem cells with radiation. Transl Oncol 4: 227-233, 2011.